No connection

Search Results

UFPT

NEUTRAL
$198.68 Live
UFP Technologies, Inc. · NASDAQ
Target $324.5 (+63.3%)
$182.87 52W Range $274.93
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 22, 2026
Market cap
$1.53B
P/E
22.71
ROE
17.8%
Profit margin
11.3%
Debt/Equity
0.36
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
UFPT exhibits exceptional fundamental health with a perfect Piotroski F-Score of 9/9 and a very conservative debt profile. However, the stock is currently trading at a significant premium, with a current price of $198.68 well above its Graham Number ($104.01) and Intrinsic Value ($150.50). While the earnings track record is stellar, organic growth is sluggish at 1.5%, and high customer concentration (45.8% from two clients) presents a systemic risk. The combination of a high PEG ratio (3.80) and bearish insider activity suggests the stock is currently overvalued despite its operational excellence.

Key Strengths

Perfect Piotroski F-Score (9/9) indicating peak financial health
Strong liquidity with a Current Ratio of 2.69 and low Debt/Equity of 0.36
Exceptional earnings track record with consistent beats over 25 quarters
Dominant position in the high-barrier medical device contract manufacturing space
Strong 5-year price performance (+289.1%) reflecting long-term scalability

Key Risks

Severe customer concentration: Intuitive Surgical and Stryker account for 45.8% of sales
Weak organic growth (1.5%) suggesting reliance on acquisitions for top-line expansion
High valuation relative to growth (PEG Ratio of 3.80)
Operational headwinds from the 'AJR Labor Issue' resulting in $6.3M in incremental costs
Bearish insider sentiment with recent officer selling and no buy transactions
AI Fair Value Estimate
Based on comprehensive analysis
$162.5
-18.2% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
57
Moderate
Value
40
Future
50
Past
95
Health
100
Dividend
0
AI Verdict
High-quality company trading at a premium price.
Key drivers: Piotroski 9/9, Customer Concentration, Valuation Gap, Organic Growth Rate
Confidence
90%
Value
40/100

Ref P/E, PEG, Graham Number

Positives
  • Forward P/E (17.35) is reasonable for the sector
Watchpoints
  • Price is 90% above Graham Number
  • Price is 32% above Intrinsic Value
  • PEG ratio of 3.80 indicates overvaluation relative to growth
Future
50/100

Ref Growth rates

Positives
  • Strategic acquisition pipeline
  • Strong analyst target price ($324.50)
Watchpoints
  • Organic growth is nearly stagnant at 1.5%
  • Inflationary pressures on labor and materials
Past
95/100

Ref Historical trends

Positives
  • Consistent earnings surprises (3/4 last 4 quarters)
  • Massive 5-year capital appreciation
Watchpoints
  • Recent 1-year return is slightly negative (-5.7%)
Health
100/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Piotroski F-Score 9/9
  • Very low Debt/Equity (0.36)
  • Strong Current Ratio (2.69)
Watchpoints
No urgent risks highlighted.
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0% payout ratio

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$198.68
Analyst Target
$324.5
Upside/Downside
+63.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for UFPT and closest competitors.

Updated 2026-04-21
UFP
UFP Technologies, Inc.
Primary
5Y
+289.1%
3Y
+40.8%
1Y
-5.7%
6M
-1.3%
1M
+5.3%
1W
+1.4%
IOV
Iovance Biotherapeutics, Inc.
Peer
5Y
-87.4%
3Y
-32.7%
1Y
+20.9%
6M
+76.2%
1M
-23.6%
1W
+7.9%
NBT
Nanobiotix S.A.
Peer
5Y
+91.8%
3Y
+705.8%
1Y
+855.9%
6M
+12.8%
1M
-6.4%
1W
+5.6%
AXG
Axogen, Inc.
Peer
5Y
+76.4%
3Y
+203.1%
1Y
+75.6%
6M
+145.6%
1M
+0.6%
1W
+5.8%
IMC
Immunocore Holdings plc
Peer
5Y
-3.6%
3Y
-38.5%
1Y
+20.3%
6M
-4.2%
1M
-4.5%
1W
+0.7%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
22.71
Forward P/E
17.35
PEG Ratio
3.8
P/B Ratio
3.62
P/S Ratio
2.54
EV/Revenue
2.77
EV/EBITDA
14.86
Market Cap
$1.53B

Profitability

Profit margins and return metrics

Profit Margin 11.33%
Operating Margin 14.1%
Gross Margin 28.27%
ROE 17.82%
ROA 9.05%

Growth

Revenue and earnings growth rates

Revenue Growth +3.4%
Earnings Growth +6.8%
Q/Q Revenue Growth +3.36%
Q/Q Earnings Growth +7.3%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.36
Low debt
Current Ratio
2.69
Strong
Quick Ratio
1.45
Good
Cash/Share
$2.63

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.1B
Gross Margin
28.2%
Op. Margin
14.1%
Net Margin
11.8%
Total Assets
$0.7B
Liabilities
$0.2B
Equity
$0.4B
Debt/Equity
0.55x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
77%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-02-24
$2.44
+9.2% surprise
2025-11-03
$2.11
+3.8% surprise
2025-08-04
$2.5
+11.1% surprise

Healthcare Sector Comparison

Comparing UFPT against 502 companies in the Healthcare sector (29 bullish, 154 neutral, 319 bearish)
P/E Ratio
22.71
This Stock
vs
83.82
Sector Avg
-72.9% (Discount)
Return on Equity (ROE)
17.82%
This Stock
vs
-94.61%
Sector Avg
-118.8% (Below Avg)
Profit Margin
11.33%
This Stock
vs
-15.81%
Sector Avg
-171.7% (Weaker)
Debt to Equity
0.36
This Stock
vs
2.86
Sector Avg
-87.3% (Less Debt)
Revenue Growth
3.4%
This Stock
vs
136.45%
Sector Avg
-97.5% (Slower)
Current Ratio
2.69
This Stock
vs
4.65
Sector Avg
-42.3% (Weaker)

Similar Companies

Peer comparison within the same industry

UFPT UFP Technologies, Inc.
NEUTRAL
Mkt Cap
$1.5B
P/E
22.7
ROE
17.8%
Price
$198.68
IOVA Iovance...
NEUTRAL
Mkt Cap
$1.5B
P/E
-
ROE
-55.5%
Price
$3.7
 Compare with UFPT
NBTX Nanobiotix S.A.
BEARISH
Mkt Cap
$1.5B
P/E
-
ROE
-%
Price
$31.83
 Compare with UFPT
AXGN Axogen, Inc.
NEUTRAL
Mkt Cap
$1.5B
P/E
-
ROE
-1.9%
Price
$32.83
 Compare with UFPT
IMCR Immunocore Holdings plc
BEARISH
Mkt Cap
$1.6B
P/E
-
ROE
-9.6%
Price
$31.05
 Compare with UFPT

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

OBERDORF THOMAS W
Director
Option Exercise
2026-03-11
2,864 shares · $63,065
LATAILLE RONALD J
Chief Financial Officer
Stock Award
2026-02-10
5,578 shares
BAILLY R JEFFREY
Chief Executive Officer
Stock Award
2026-02-10
26,489 shares
ROCK MITCHELL CAPLAN
President
Stock Award
2026-02-10
5,733 shares
LITTERIO CHRISTOPHER P
Officer
Stock Award
2026-02-10
2,036 shares
HOLT JASON
Officer
Stock Award
2026-02-10
1,778 shares
BAILLY R JEFFREY
Chief Executive Officer
Stock Award
2025-12-19
1,744 shares
HOLT JASON
Officer
Sell
2025-12-10
100 shares · $21,358
HOLT JASON
Officer
Gift
2025-11-25
70 shares · $15,525
LITTERIO CHRISTOPHER P
Officer
Sell
2025-11-06
1,829 shares · $415,550
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-02-27

UFPT filed a current report on February 27, 2026, likely to announce its annual financial results.

10-K
10-K
2026-02-27

UFP Technologies reported 2025 net sales of $602.8 million, a 19.5% increase driven primarily by strategic acquisitions, while organic growth remained modest at 1.5%. The company faces significant customer concentration, with Intuitive Surgical and Stryker accounting for 45.8% of total net sales. Key risks include workforce turnover resulting from E-Verify reviews at AJR and potential margin compression due to inflationary pressures on manufacturing and labor costs.

8-K
8-K
2026-02-24

UFPT filed a current report on February 24, 2026, likely announcing its annual financial results for the 2025 fiscal year.

8-K
8-K
2026-02-24

UFPT filed a current report on February 24, 2026, likely announcing its annual financial results for the 2025 fiscal year.

8-K
8-K
2026-02-24

UFPT filed a current report on February 24, 2026, likely announcing its annual financial results for the 2025 fiscal year.

8-K
8-K
2026-02-13

UFPT likely filed this 8-K to announce its fourth-quarter and full-year financial results.

8-K
8-K
2025-12-02
8-K
8-K
2025-12-02
10-Q
10-Q
2025-11-07

UFPT filed its 10-Q on November 7, 2025. The filing includes a section dedicated to Risk Factors, although specific financial highlights and detailed risk disclosures were not provided in the available excerpts.

8-K
8-K
2025-11-03

UFPT filed an 8-K on November 3, 2025, likely to report its third-quarter financial results.

8-K
FORM 8-K
2025-08-21
10-Q
FORM 10-Q
2025-08-11
8-K
FORM 8-K
2025-08-05
8-K
FORM 8-K
2025-07-17
8-K
FORM 8-K
2025-06-10
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning UFPT from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile